Hubbry Logo
Wada testWada testMain
Open search
Wada test
Community hub
Wada test
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Wada test
Wada test
Wada test
View on Wikipedia
from Wikipedia
Wada test
SynonymsIntracarotid sodium amobarbital procedure
Purposeestablishes cerebral language and memory

The Wada test, also known as the intracarotid sodium amobarbital procedure (ISAP) or Wada-Milner Test, establishes cerebral language and memory representation of each hemisphere.

Method

[edit]

Medical professionals conduct the test with the patient awake. A barbiturate, usually sodium amobarbital, is introduced into one of the internal carotid arteries via a cannula or intra-arterial catheter from the femoral artery. The drug is injected into one hemisphere at a time through the right or left internal carotid artery. If the right carotid is injected, the right side of the brain is inhibited and cannot communicate with the left side. The effect shuts down any language and/or memory function in that hemisphere in order to evaluate the other hemisphere. An EEG recording at the same time confirms that the injected side of the brain is inactive as a neurologist performs a neurological examination. The neurologist engages the patient in a series of language and memory related tests. They evaluate the memory by showing a series of items or pictures to the patient and—within a few minutes, as soon as the effect of the medication dissipates—testing the patient's ability to recall.[1] The test is typically administered by a neuropsychologist as a result of expertise in psychometric testing. Correlation with formal neuropsychological testing has some predictive power regarding seizure outcome following anterior temporal lobectomy.[2]

There is currently great variability in the processes used to administer the test, and so it is difficult to compare results from one patient to the other.[3]

Uses

[edit]

The test is usually performed prior to ablative surgery for epilepsy and sometimes prior to tumor resection. The aim is to determine which side of the brain is responsible for certain vital cognitive functions, namely speech and memory. The risk of post-operative cognitive change can be estimated, and depending on the surgical approach employed at the epilepsy surgery center, the need for awake craniotomies can be determined as well.[citation needed]

The Wada test has several side-effects. Drastic personality changes are rarely noted, but disinhibition is common. Also, contralateral hemiplegia, hemineglect and shivering are often seen.[citation needed] After injection on the side of the speech-dominant hemisphere, typically the left, the patient experiences transient aphasia, ie. impaired speech and language or the inability to express or understand language.[4] Though the patient may not be able to talk, sometimes their ability to sing is preserved.[citation needed] This is because music and singing uses a different part of the brain than speech and language.[citation needed] Recovery from the anesthesia is rapid, and EEG recordings and distal grip strength may be used to determine when the medication has worn off. Generally, recovery of speech is dysphasic (contains errors in speech or comprehension) after a language dominant hemisphere injection.[citation needed]

Though generally considered a safe procedure, there are at least minimal risks associated with the angiography procedure that guides the catheter to the internal carotid artery, perhaps related to the physician's experience.[citation needed] Researchers are looking into non-invasive ways to determine language and memory laterality—such as fMRI, TMS, magnetoencephalography, and near-infrared spectroscopy.[citation needed]

History

[edit]

The Wada test is named after Japanese neurologist and epileptologist Juhn Atsushi Wada, of the University of British Columbia.[5][6] He developed the test while he was a medical resident in Japan just after[citation needed] World War II, when he was receiving training in neurosurgery. Wada developed the technique of transient hemispheric anesthetization through carotid amytal injection to decrease the cognitive side effects associated with bilateral electroconvulsive therapy.[7] He published the initial description of motor, sensory, language, and effects on the "conscious state" in 1949, in Japanese. During his fellowship at the Montreal Neurological Institute, he introduced the test to Dr. Brenda Milner and associates, who modified the test to assess language laterality and memory function prior to a unilateral lobectomy. As this is now the primary use of the procedure, some neuropsychologists argue for it to be renamed the Wada-Milner Test in recognition of her significant contributions.[8][9]

[edit]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Wada test

View on Grokipedia
from Grokipedia
The Wada test, also known as the intracarotid sodium amobarbital procedure (ISAP), is a specialized diagnostic examination designed to assess the functional dominance of each cerebral hemisphere for language and memory, primarily in patients with epilepsy who are candidates for resective brain surgery. Developed to minimize postoperative risks such as aphasia or amnesia, the test involves temporarily anesthetizing one side of the brain at a time through an injection of a short-acting barbiturate, allowing clinicians to evaluate cognitive functions while the patient remains awake. It remains a gold standard in preoperative epilepsy evaluation, despite emerging noninvasive alternatives like functional MRI. The procedure is typically conducted in a specialized suite by a multidisciplinary team, including an epileptologist, neuroradiologist, and neuropsychologist. It begins with insertion into the in the , followed by to visualize cerebral vessels, after which is injected into one to sedate the corresponding hemisphere for about 10-15 minutes. During this period, the patient undergoes rapid assessments of speech comprehension, naming, repetition, and reading, as well as tasks using or story recall presented just before injection. The process is repeated for the contralateral side, with the entire test lasting 3-4 hours, often as an outpatient procedure requiring preparation such as and avoidance of thinners. Originating in the late 1940s, the Wada test was pioneered by Japanese neurologist Juhn A. Wada (later a Canadian citizen) at in , who first reported its use in 1949 for localizing language areas in patients through unilateral injection. Building on earlier work with cortical anesthetics, Wada's innovation enabled safer preoperative mapping without invasive . In the 1960s, collaboration with neuropsychologist at the Montreal Neurological Institute expanded the test to include memory evaluation, significantly improving predictions of surgical outcomes in cases. Although risks are low—primarily temporary , , or rare vascular complications—the test's invasiveness has prompted its gradual replacement by advanced imaging in select patients, yet it retains utility in ambiguous or high-stakes scenarios.

Background and Purpose

Definition and Mechanism

The Wada test, also known as the intracarotid amobarbital procedure (IAP), is a diagnostic method that involves the injection of sodium amobarbital, a short-acting , into the to temporarily anesthetize one for approximately 5-10 minutes. This procedure allows clinicians to isolate and evaluate the functional contributions of each hemisphere, particularly for and , by observing the effects of unilateral inactivation. Originally developed for evaluation, it simulates the impact of surgical resection on brain function. The mechanism of the Wada test relies on 's pharmacological action, which primarily enhances inhibitory neurotransmission at GABA_A receptors, leading to suppression of neuronal activity in the injected hemisphere. This results in reduced cerebral blood flow (hypoperfusion) and metabolic activity, particularly in medial temporal structures, causing temporary contralateral hemiplegia, if the dominant hemisphere is affected, and characteristic theta-delta patterns on (EEG). Injection into the targets the anterior and territories, which supply the frontal, temporal, and parietal lobes, while sparing the posterior circulation supplied by the vertebral-basilar system to avoid broader effects. The effect onset is rapid, occurring within seconds of the 75-125 mg bolus, enabling targeted assessment before recovery begins. Central to the test's utility are concepts of hemispheric dominance and contralateral function. In most right-handed individuals (approximately 95%), is lateralized to the left hemisphere, while functions are often bilateral but with variable dominance; the Wada test reveals these asymmetries by demonstrating preserved or impaired performance when one side is inactivated. Contralateral motor effects, such as , confirm adequate hemispheric suppression, ensuring reliable evaluation of cognitive tasks from the intact side. This approach provides critical insights into functional organization without permanent damage.

Clinical Indications

The Wada test serves as a primary preoperative evaluation tool in , particularly for patients undergoing , where it confirms the lateralization of and functions to predict potential postoperative deficits. It is indicated for individuals with drug-refractory and a unilateral seizure focus, typically supported by normal of the contralateral hemisphere and inconclusive results from noninvasive assessments such as functional MRI (fMRI). This evaluation helps determine the functional reserve in the unaffected hemisphere, guiding surgical decisions to minimize risks of or following resection. Secondary applications include assessment prior to brain tumor resection or other neurosurgical procedures that may compromise hemispheric function, such as in cases involving gliomas near eloquent areas like the inferior frontal or superior temporal gyri. The test is particularly valuable for evaluating atypical language dominance, which occurs more frequently in left-handed individuals (up to 30-40% atypical lateralization) or bilingual patients, where noninvasive methods may fail to accurately map hemispheric contributions. Patient selection emphasizes candidates with who exhibit equivocal fMRI findings or bilateral language representation, ensuring the procedure addresses uncertainties in hemispheric specialization. As of 2025, the Wada test remains essential in scenarios where fMRI results are unreliable, though its overall use has declined with advances in imaging; surveys indicate it is performed in approximately 20-40% of epilepsy centers, often limited to complex cases.

Procedure

Preparation

Prior to undergoing the Wada test, patients receive a comprehensive to ensure suitability and establish baseline function. This includes a detailed to assess overall health and history, often conducted by an epileptologist or neurologist. is performed beforehand to map cerebral vascular anatomy and confirm adequate blood flow to the regions of interest, typically involving insertion via the and injection of contrast dye under guidance. Baseline cognitive testing, administered by a neuropsychologist, evaluates memory recall, abilities, and intellectual function (such as IQ screening to exclude those with severe impairment, e.g., IQ below 70), providing a reference for intra-procedure assessments. The process is a critical step, where the multidisciplinary team—typically including a neurosurgeon, neuropsychologist, and neuroradiologist—explains the procedure in detail to the patient. This covers temporary effects like or confusion on the injected side, potential for seizures during the test, and rare risks of permanent neurological deficits or allergic reactions. Patients are encouraged to ask questions, and written is obtained only after full comprehension, emphasizing the test's role in guiding surgery. Logistically, the Wada test is conducted in a specialized neurointerventional suite equipped for real-time monitoring, such as continuous EEG to track activity. The team present includes an interventional neuroradiologist for catheter management, a neuropsychologist for cognitive oversight, an epileptologist, staff, and sometimes a speech- pathologist to aid in evaluation. Patients must fast for at least 8 hours prior (no food or drink after midnight, with morning medications allowed using sips of water), similar to requirements for , to minimize risks during . Screening for contraindications occurs during , focusing on allergies to contrast agents, anesthetics (e.g., barbiturates or iodine dyes), or conditions like severe ; medications such as aspirin or blood thinners are discontinued 1-2 weeks in advance. Bilateral testing is often performed sequentially on the same day or over separate sessions to allow recovery between injections. Patients arrive early (e.g., 15-30 minutes) with identification, details, and a companion for transportation home, as the procedure spans 4-10 hours including preparation and observation.

Execution and Assessment

The execution of the Wada test begins with the insertion of a via the , which is advanced to the supplying the hemisphere under evaluation. An angiogram is typically performed beforehand to map the vascular and confirm catheter placement. Once positioned, a bolus of 75-125 mg of sodium is injected slowly over 5-10 seconds into the , with additional incremental doses of 12.5 mg administered if needed to achieve adequate hemispheric inactivation. The injection is confirmed by the onset of contralateral hemiplegia (typically within 15-30 seconds) and EEG changes showing theta-delta slowing in the injected hemisphere, indicating successful of the anterior two-thirds of the for approximately 5-10 minutes. Continuous video and EEG recording is maintained throughout to monitor patient responses, detect any seizures, and document behavioral changes. Assessment protocols commence immediately after confirmation of inactivation. Language testing, conducted within 1-2 minutes of injection while the hemisphere is anesthetized, evaluates dominance through tasks such as naming objects, reading sentences, and comprehending spoken or written commands. A scoring system quantifies deficits to calculate a laterality index based on percentage of correct responses across injections, with significant asymmetry (e.g., laterality index >50) indicating language dominance in the non-inactivated hemisphere. Memory evaluation follows, starting 2-5 minutes post-injection, to assess encoding and storage capabilities. Patients are presented with stimuli for story recall (e.g., narrating a short passage) and visual recognition (e.g., identifying objects or scenes from cards), which they must remember for later retrieval after the drug effects subside. is scored based on performance by comparison to baseline and contralateral testing to determine hemispheric contribution. The process for each hemisphere lasts approximately 10-15 minutes, after which the patient recovers motor function. The contralateral hemisphere is then tested by repositioning the , allowing at least 30 minutes for full recovery to avoid cumulative effects.

Recovery and Follow-Up

Following the Wada test, patients are transferred to a recovery unit for close monitoring, typically lasting 1 to 4 hours, to ensure resolution of temporary effects such as , fluctuations in , and any potential activity. The induced contralateral , a normal response to the injection, generally resolves within 15 to 30 minutes as the drug's effects dissipate, allowing for assessment of full neurological recovery. During this period, staff frequently check the puncture site for bleeding or formation, monitor , and ensure the patient remains flat in bed with the affected leg straight to promote . Patients are encouraged to drink fluids to flush the contrast dye and resume once alert, with most feeling back to baseline within 20 to 30 minutes post-procedure. If stable, patients are discharged the same day, usually after 4 to 6 hours of observation, with rare instances requiring overnight admission for persistent symptoms. Post-discharge instructions emphasize rest for 72 hours, limiting activity to light walking on the first day and avoiding driving for 48 hours or strenuous exertion to minimize complications at the access site. Patients must arrange for a driver home and monitor the area for signs of or , contacting their care team if issues arise. In follow-up, Wada test results are integrated with complementary data from modalities such as and to inform planning, particularly in localizing epileptogenic zones while preserving eloquent areas. Interpretation focuses on and lateralization; for instance, bilateral representation occurs in approximately 5% to 25% of patients, influencing resection strategies to avoid global deficits. asymmetry identified by the test guides the side of resection, as inadequate contralateral support predicts higher risk of postoperative decline following temporal , occurring in over 30% of cases with left-sided procedures. Patients receive counseling on these predicted deficits, including the potential for loss, to weigh surgical benefits against risks. Re-testing may be required if clinical changes suggest shifts in hemispheric function due to .

Risks and Limitations

Potential Complications

The Wada test, involving temporary hemispheric inactivation via intracarotid anesthetic injection, is associated with expected transient effects that are integral to its diagnostic purpose. Contralateral occurs in nearly all cases (approximately 100%) as the anesthetic disrupts motor function in the injected hemisphere, typically resolving within minutes to hours. Similarly, or arises during dominant hemisphere inactivation in most patients, lasting 5-15 minutes and allowing assessment of lateralization, while non-dominant injections may cause milder disorientation. Post-procedure and are common mild effects, often attributable to contrast dye or insertion, affecting up to 20-30% of patients but usually self-limiting within hours. Rare serious complications include or (0.6-1%), transient ischemic attacks (0.6%), induced seizures (1-2%), , and at the catheter site. These events stem primarily from vascular access risks, such as from catheter manipulation or anesthetic migration. Incidence is higher in patients with vascular anomalies, where rates may exceed 10% due to challenges in catheter placement. Overall complication rates range from 2-11% across studies, with no reported long-term morbidity or mortality in large cohorts; a 2015 review of 431 patients reported 2.1% clinical complications, lower than the 10.9% in a 2008 analysis of 677 cases. Recent data up to 2024 indicate persistent low incidence (<5% for serious events) when performed in experienced centers, though up to 10-30% of tests may yield unsatisfactory results due to transient side effects. Mitigation strategies include real-time for precise guidance and heparin flushing to prevent , reducing vascular risks during the procedure. Immediate monitoring allows for rapid intervention, such as anticonvulsants for seizures, further minimizing adverse outcomes.

Contraindications and Patient Considerations

The Wada test carries relative contraindications in cases of severe or carotid exceeding 70%, as the invasive catheterization risks dislodging atherosclerotic plaques and causing embolic events. Uncontrolled similarly requires careful management due to heightened vulnerability to cerebrovascular complications during arterial manipulation. to amobarbital, the primary anesthetic agent, is a requiring alternative agents to prevent adverse reactions. Relative contraindications encompass , where potential fetal exposure to and contrast agents must be weighed against benefits; bleeding disorders, including , which elevate hemorrhage risks at the site; and recent , as it may exacerbate ischemic vulnerabilities. Pediatric application is restricted by the requirement for patient cooperation and reliable communication, generally limiting use to those older than 8 years who can actively participate in cognitive assessments. Patient-specific considerations are essential to optimize safety and validity. For individuals with high anxiety, alternative sedation options—such as anxiolytics or instead of —can facilitate cooperation without compromising hemispheric inactivation. Non-native English speakers may require language-matched testing materials or interpreters to mitigate misinterpretation of aphasia-like deficits induced by the . Ethical challenges in arise for patients with cognitive impairments, often necessitating involvement of legal guardians, simplified verbal explanations, or advance directives to ensure comprehension of procedural risks. Gender-based differences in Wada test outcomes are minimal, with similar and lateralization patterns across sexes. However, left-handed individuals warrant cautious interpretation, as they exhibit higher rates of bilateral or language dominance (approximately 15%), potentially leading to inconclusive results.

Alternatives and Advances

Non-Invasive Techniques

Functional magnetic resonance imaging (fMRI) serves as a primary non-invasive alternative to the Wada test, particularly for assessing lateralization through activation tasks such as verb generation or semantic decision-making. These tasks elicit blood-oxygen-level-dependent (BOLD) signals in language-dominant regions, typically showing greater than 90% concordance with Wada test results in low-risk patients without atypical language representation. However, fMRI's utility is limited for lateralization, where concordance rates drop to around 47% compared to the Wada test, due to challenges in capturing hippocampal activation reliably. The adoption of fMRI in centers has grown substantially, with many institutions now using it routinely for preoperative mapping, reflecting a shift toward safer, repeatable imaging. Magnetoencephalography (MEG) provides another non-invasive method for mapping eloquent cortex, measuring magnetic fields from neuronal currents to localize language and motor areas during tasks like auditory or picture naming. MEG excels in , identifying activation peaks in the and with sensitivity comparable to invasive methods in select cases, and it avoids the spatial distortions of fMRI near air-tissue interfaces. For patients, MEG aids in onset zone identification and functional mapping, often integrated with MRI for source to guide resection while preserving critical areas. Emerging hybrid approaches, such as MEG-fMRI combinations, enhance localization by leveraging MEG's timing precision with fMRI's spatial detail, improving network delineation in complex cases. Less invasive variants of the Wada test, like superselective Wada using micro-catheters for targeted anesthetic injection into specific arterial branches, reduce systemic effects while assessing localized function, though they still involve catheterization. Despite these advances, non-invasive techniques have not fully supplanted the Wada test for high-stakes memory prediction in surgical planning, as they require validation in diverse patient populations.

Comparative Effectiveness

The Wada test serves as the historical gold standard for assessing hemispheric dominance of language and memory functions prior to epilepsy surgery, demonstrating near-perfect reliability (95-100%) in lateralizing language in patients with typical left-hemisphere dominance. Functional MRI (fMRI), a primary non-invasive alternative, shows 85-95% concordance with the Wada test for language lateralization, though discordance rises to 40% in cases of bilateral representation. For memory lateralization, fMRI concordance drops to approximately 79% in unilateral cases and as low as 47% overall, with false negatives occurring in 10-15% of temporal lobe epilepsy patients due to challenges in detecting subtle asymmetries. Electrocorticography (ECoG), while invasive and limited to intraoperative use, offers superior spatial resolution for localizing language areas, achieving 79% specificity compared to electrical stimulation mapping, surpassing the Wada test's broader hemispheric focus. Non-invasive methods like fMRI substantially improve safety profiles, with complication rates below 0.1% (essentially zero for routine imaging risks such as or contrast reactions), in contrast to the Wada test's 1-11% complication rate, including transient (7%), seizures (1%), and rare strokes (0.6-1.2%). Cost-effectiveness further favors fMRI, which incurred direct costs about one-third those of the Wada test (approximately $300 versus $1,130 per procedure as of 2004), making it preferable for routine presurgical evaluations in resource-limited settings. The Wada test retains applicability in 20-30% of complex cases where non-invasive results are discordant or fail to confirm bilateral independence, such as in atypical language dominance or when fMRI yields inconclusive data. According to the 2023 National Association of Epilepsy Centers (NAEC) guidelines (published 2024), the Wada test should be reserved for situations where non-invasive tests like fMRI or are inconclusive, emphasizing its selective use to balance risks and benefits. A trend toward "Wada-less" protocols has emerged, reflecting a decline from 81% utilization in 1997 to 14% by 2007 and continued reduction thereafter.

History and Development

Origins

The Wada test, also known as the intracarotid amobarbital procedure, was developed by Japanese neurologist Juhn Atsushi Wada in the late 1940s while he was working at Hokkaido Imperial University Hospital in Sapporo, Japan, shortly after obtaining his medical license in 1947. Wada, who had graduated from Hokkaido Imperial University in 1946 amid the challenges of postwar Japan, sought innovative methods to evaluate brain function in epilepsy patients during a time when diagnostic options were limited. His work built on earlier animal research, including his own experiments where unilateral intracarotid injection of the barbiturate amobarbital demonstrated the ability to anesthetize one cerebral hemisphere and prevent the bilateral propagation of seizures, providing a model for selective hemispheric inactivation without generalized effects. The initial rationale for the test stemmed from the need to reduce cognitive side effects of (ECT) for psychiatric disorders by temporarily anesthetizing the language-dominant hemisphere, allowing unilateral treatment. This approach was first applied clinically in to a experiencing prolonged focal motor , marking the inaugural human use of the procedure to evaluate hemispheric function in an context. Wada's findings were published in 1949 in the Japanese journal Medicine and Biology, in a preliminary report titled "A new method for the determination of the side of cerebral speech dominance: A preliminary report on the intracarotid injection of sodium Amytal in man," which detailed the technique's utility for identifying language lateralization and laid the groundwork for its application in planning. Although developed in , the test gained international recognition after Wada's 1954 sabbatical at the Neurological Institute, where he collaborated with neurosurgeon to refine and integrate it into preoperative evaluations for , adapting it further for assessment.

Evolution and Current Status

Following its initial development in the late 1940s, the Wada test underwent significant procedural refinements that established it as a cornerstone of evaluation. By the , it had become a standalone method for determining hemispheric dominance for and , making it routine in preoperative assessments for temporal . Further evolutions in the focused on dosage to enhance and . Early applications varied widely in amounts, but studies from this period refined protocols, increasing average doses from approximately 87 mg (1966–1970) to 110 mg thereafter, which improved consistent hemispheric inactivation while reducing systemic side effects like respiratory depression. By the 1990s, integration with advancing modalities, such as functional MRI (fMRI), began to complement the test; correlational studies demonstrated that fMRI language activation patterns aligned with Wada results in the frontal lobes, enabling hybrid approaches for more precise presurgical mapping. The test's role has notably declined in routine clinical practice over recent decades, reflecting the rise of non-invasive alternatives. In the , it was employed in about 85% of evaluations for and lateralization, but usage has dropped to 20–30% by the 2020s, particularly in centers adopting fMRI and () for initial assessments. Despite this, the Wada test remains essential for validating results in ambiguous cases, such as those with atypical representation or discordant noninvasive findings. As of 2025, the International League Against Epilepsy (ILAE) regards the Wada test as the invasive gold standard for functional lateralization, though guidelines recommend its selective use due to procedural risks, prioritizing it when noninvasive methods are inconclusive. Ongoing research emphasizes safer variants, including propofol-based intracarotid injections, which have demonstrated comparable efficacy to amobarbital with fewer adverse effects in pediatric and adult cohorts, and superselective IAP techniques that target specific arterial branches to minimize global hemispheric disruption. The passing of Juhn Wada in 2023 concluded the era of its originator's direct influence, yet the procedure endures as a benchmark in contemporary neurology for high-stakes epilepsy and tumor resections.

References

  1. https://my.clevelandclinic.org/health/diagnostics/17628-wada-test
  2. https://www.hopkinsmedicine.org/health/conditions-and-diseases/epilepsy/wada-testing
  3. https://med.emory.edu/departments/neurology/_documents/loring_meador_wada_history_chapter.pdf
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9562037/
  5. https://thejns.org/view/journals/j-neurosurg/17/2/article-p266.xml
  6. https://pubmed.ncbi.nlm.nih.gov/17564192/
  7. https://www.sciencedirect.com/topics/neuroscience/amobarbital
  8. https://pubmed.ncbi.nlm.nih.gov/10319745/
  9. https://www.sciencedirect.com/science/article/pii/S0278262697908848
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC8117406/
  11. https://www.epilepsy.com/treatment/surgery/tests-surgery/wada-test
  12. https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.884730/full
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC5243162/
  14. https://link.springer.com/article/10.1007/s00234-020-02397-w
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7406510/
  16. https://www.sciencedirect.com/science/article/abs/pii/S1525505020302444
  17. https://www.nm.org/-/media/Northwestern/Resources/care-areas/neurosciences/northwestern-medicine-wada-test-nmh.pdf?la=en
  18. https://www.pennmedicine.org/treatments/wada-testing
  19. https://www.cottagehealth.org/services/epilepsy/wada-testing/preparing-for-the-wada-test/
  20. https://pubmed.ncbi.nlm.nih.gov/24276596/
  21. https://www.brighamandwomens.org/neurosciences-center/epilepsy-and-seizure-disorders/more-information-on-tests
  22. https://www.cottagehealth.org/services/epilepsy/wada-testing/what-to-expect-after-the-wada-test/
  23. https://neupsykey.com/wada-test/
  24. https://www.epilepsy.com/treatment/surgery/tests-surgery
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC3463744/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC2943848/
  27. https://www.neurology.org/doi/10.1212/WNL.45.7.1329
  28. https://aesnet.org/abstractslisting/repeating-the-wada-test--how-often--why--and-with-what-results
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC4727656/
  30. https://www.researchgate.net/publication/7614200_Evaluation_of_adverse_effects_in_intracarotid_propofol_injection_for_WADA_test
  31. https://pubmed.ncbi.nlm.nih.gov/18590981/
  32. https://resources.wfsahq.org/wp-content/uploads/atow-474.pdf
  33. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13046
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC10858922/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC10209854/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC7976364/
  37. https://www.epilepsysco.org/about-epilepsy/testing/wada-test/
  38. https://www.jvir.org/article/S1051-0443(15)00655-7/pdf
  39. https://www.sciencedirect.com/science/article/pii/S1059131113002860
  40. https://pubmed.ncbi.nlm.nih.gov/21335292/
  41. https://www.aafp.org/pubs/afp/issues/2000/0115/p400.html
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC3008762/
  43. https://pubs.rsna.org/doi/10.1148/radiol.11101344
  44. https://thejns.org/view/journals/j-neurosurg/100/5/article-p867.xml
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC6584755/
  46. https://aesnet.org/abstractslisting/concordance-of-fmri-and-meg-for-presurgical-language-lateralization-in-children-with-epilepsy
  47. https://www.sciencedirect.com/science/article/pii/S2667242122000549
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC3649863/
  49. https://www.sciencedirect.com/science/article/abs/pii/S1525505017306741
  50. https://www.sciencedirect.com/science/article/abs/pii/S1525505008001510
  51. https://pubs.rsna.org/doi/abs/10.1148/radiol.2301021122
  52. https://www.neurology.org/doi/10.1212/WNL.0000000000208087
  53. https://pubmed.ncbi.nlm.nih.gov/20940113/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC10513887/
  55. https://pubmed.ncbi.nlm.nih.gov/8564293/
  56. https://link.springer.com/content/pdf/10.1007/978-1-4612-2874-5.pdf
  57. https://www.neurology.org/doi/10.1212/WNL.54.8.1625
  58. https://www.researchgate.net/publication/283551891_The_Wada_Test_Current_Perspectives_and_Applications
  59. https://www.sciencedirect.com/science/article/abs/pii/S0920121121001261
  60. https://www.researchgate.net/publication/47403460_Incidence_and_clinical_decision_making_for_the_Wada_test_over_one_decade_1997-2007
  61. https://www.ilae.org/about-ilae/in-memoriam/in-memoriam-recent-and-archive-deaths/juhn-wada-1924-2023
  62. https://pubmed.ncbi.nlm.nih.gov/29169082/
  63. https://pmc.ncbi.nlm.nih.gov/articles/PMC3806007/
  64. https://bcmj.org/obituaries/dr-juhn-atsushi-wada-1924-2023
Add your contribution
Related Hubs
User Avatar
No comments yet.